KEYWORDS: USP7; CDK1; DNA REPLICATION; MITOSIS; S/M TRANSITION. USP7 coordinates the S/M transition 2 Galarreta et al. SUMMARY To ensure a faithful segregation of chromosomes, DNA must be fully replicated before mitotic entry. However, how cells sense the completion of DNA replication and to what extent this is linked to the activation of the mitotic machinery remains poorly understood. We previously showed that USP7 is a replisome-associated deubiquitinase with an essential role in DNA replication. Here, we reveal that USP7 inhibition leads to the ubiquitination of MCM7, a hallmark of DNA replication termination. In addition, USP7 inhibition leads to the ubiquitination of additional replisome components such as POLD1, which are displaced from replisomes. Surprisingly, this premature termination of DNA replication occurs concomitant to a generalized activation of CDK1 throughout the entire cell cycle, which impairs chromosome segregation and is toxic for mammalian cells. Accordingly, the toxicity of USP7 inhibitors is alleviated by CDK1 inhibition. Our work sheds light into the mechanism of action of USP7 inhibitors and provides evidence to the concept that DNA replication termination is coupled to the activation of the mitotic program. USP7 coordinates the S/M transition 3 Galarreta et al.
INTRODUCTION
The eukaryotic cell cycle is governed by cyclin/CDK complexes that coordinate an orderly transition between the different cell cycle stages (G1, S, G2 and M). As noted early on, among the different transitions, limiting mitotic entry before DNA replication is completed is of particular relevance (Enoch & Nurse, 1991 , Hartwell & Weinert, 1989 . Besides the fact that unreplicated loci physically impair chromosome segregation, the premature activation of mitotic kinases in Sphase leads to chromosome pulverization and cell death (Aarts, Sharpe et al., 2012 , Duda, Arter et al., 2016 . Likewise, early works revealed that the fusion of a mitotic cell with an interphase cell triggers premature chromosome condensation (PCC) in the later (Johnson & Rao, 1970) . Consistent with the key role of CDK1 in the G2/M transition, premature mitotic entry can be induced by genetic or chemical strategies that increase CDK1 activity, such as wee1 deletion in fission yeast (Russell & Nurse, 1987) , or the use of WEE1, ATR or phosphatase inhibitors in mammalian cells (Aarts et al., 2012 , Ajiro, Yoda et al., 1996 , Ruiz, Mayor-Ruiz et al., 2016 . In this context, the main function of an S/M checkpoint should be to restrict CDK1 activity until DNA replication ends. However, while the presence of such a checkpoint has been long thought of (Hartwell & Weinert, 1989) , evidences for its existence remain missing.
In contrast to initiation or elongation, the mechanisms that drive DNA replication termination have remained unexplored until recent years (Dewar & Walter, 2017) . We now know that the dissociation of the CMG helicase (CDC45, MCM2-7 and GINS) is a key event in termination, which only occurs after the DNA from two converging forks is fully replicated and ligated (Dewar, Budzowska et al., 2015) . At the molecular level, replisome disassembly requires MCM7 ubiquitination (Maric, Maculins et al., 2014 , Moreno, Bailey et al., 2014 , which drives its extraction from chromatin by the VCP segregase and its adaptors UFD1L and NPLOC4 (Maric, Mukherjee et al., 2017 , Sonneville, Moreno et al., 2017 . In addition, the unloading of the MCM complex in late S-phase is facilitated by MCM-BP (Nishiyama, Frappier et al., 2011) . While the E3 ubiquitin ligase complex that ubiquitinates MCM7 upon DNA replication termination has been identified in C. elegans and Xenopus (CUL2 LRR1 ), its mammalian counterpart remains unknown. In this context, we recently reported that USP7 is a replisome-associated deubiquitinase (DUB) that is essential for DNA replication (Lecona, Rodriguez-Acebes et al., 2016) . Proteomic analyses revealed that USP7 inhibition increases the ubiquitination of SUMO and SUMOylated factors, which are displaced from replication factories. Interestingly, MCM7 was one of the proteins to show increased ubiquitination upon USP7 inhibition, with the modification occurring at the same region that had been linked to DNA replication termination in yeast (Maric et al., 2017) . Moreover, prior work showed that MCM-BP tethers USP7 to MCM proteins, and that lack of USP7 increases the levels of chromatin-bound MCM (Jagannathan, Nguyen et al., 2014) . Based on these data, we previously hypothesized that USP7 inhibition could be an approach to mimic DNA replication termination in mammalian cells . Here, we confirmed this hypothesis and used USP7 inhibition as a way to address the potential coordination between the completion of DNA replication and the activation of the mitotic program. 
RESULTS

USP7 inhibition triggers DNA replication termination
In order to perform a detailed analysis of the effect of USP7 inhibition on cellcycle progression, human retinal pigmentum epithelial (RPE) cells were synchronized with a double thymidine block and released in the absence or presence of the USP7 inhibitor P22077 (USP7i, hereafter; added 4 hrs after the release). While by 14 hrs control cells had completed an entire cell cycle, the treatment with USP7i led to an immediate arrest in S-phase that could not be overcome, which could be consistent with DNA replication termination ( Figure 1A) .
In support of this, and as previously observed in proteomic analyses , USP7 inhibition led to an accumulation of ubiquitinated MCM7 on chromatin, which is a hallmark of replication termination (Maric et al., 2014 , Moreno et al., 2014 (Figure 1B) . Moreover, MCM7 ubiquitination was also detected in control RPE cells at time-points coincident with mitotic entry and thus with the completion of DNA replication (8-12 hrs). Upon its ubiquitination at the end of DNA replication, MCM7 is extracted from chromatin by the action of the VCP segregase (Maric et al., 2017 , Sonneville et al., 2017 . Likewise, USP7 inhibition led to an accumulation of the VCP segregase on chromatin concomitant with MCM7 ubiquitination ( Figure   1B ). Immunofluorescence analysis in U2OS cells confirmed the recruitment of VCP to chromatin upon USP7i treatment (Figure 1C,D) .
Similar to the accumulation of VCP, our previous work showed that USP7 inhibition leads to an increase of SUMO2/3 levels on chromatin . Interestingly, while SUMO2/3 is normally enriched at replication foci, the increase of chromatin-bound SUMO2/3 triggered by USP7 inhibition occurs away from replisomes, which we suggested was due to a general displacement of SUMOylated replisome factors upon their ubiquitination exposure to USP7i (Figure 1E ). Of note, while much of the focus of DNA replication termination studies has been placed on the role of ubiquitination on the disassembly of the MCM complex (Dewar & Walter, 2017) , this mechanism could also apply to other replisome components. In this regard, we also detected an increase in DNA Polymerase delta 1 (POLD1) ubiquitination upon USP7 inhibition in late S-phase ( Figure 1B) . Immunoprecipitation experiments with histidine-tagged ubiquitin confirmed the ubiquitination of chromatin-bound POLD1 in response to USP7i ( Figure S1A) . The ubiquitination of POLD1 occurred concomitant to its accumulation on chromatin, but away from sites of DNA replication (as identified by PCNA) (Figure 1F ). Of note, other factors such as RPA2 or RFC2 are not delocalized from PCNA foci upon USP7 inhibition (Figure S1B) , arguing that the role of USP7 is not a general action on all replisome components. Collectively, these results indicate that USP7 inhibition mimics DNA replication termination, allowing us to explore the potential connection between the end of S-phase and mitotic entry.
USP7 inhibition leads to a premature activation of mitotic kinases
To investigate the effects of USP7 inhibition on the activation of the mitotic program, we first evaluated its impact on the levels of phosphorylated histone H3 Ser 10 (H3S10P), a well-established mitotic mark that is required for chromosome condensation (Wei, Yu et al., 1999) , and which was originally discovered in cells undergoing PCC (Ajiro, Nishimoto et al., 1983) . Despite the immediate arrest of DNA replication that is observed upon a treatment with USP7 inhibitors, exposure of human HCT116 cells to these agents led to a significant increase in H3S10 phosphorylation (Figure 2A) . Surprisingly, flow cytometry analyses revealed that UPS7 inhibition led to a global accumulation of H3S10P throughout the cell cycle ( Figure 2B) , rather than being restricted to mitotic cells. Similar observations were done using MPM-2, a monoclonal antibody raised against mitosis-specific phosphorylation events (Davis, Tsao et al., 1983) , which also marks sites of chromosome condensation (Rieder & Cole, 1998) (Figure 2A,B) . Importantly, these effects were observed in all cell lines tested including RPE and U2OS ( Figure   S2A,B) . Moreover, they were recapitulated with an independent USP7 inhibitor (Ritorto, Ewan et al., 2014) (Figure S2C) , and by RNA interference-mediated depletion of USP7 (Figure 2C-E) , confirming the selectivity of the effect.
Mitotic entry is primarily driven by the activation of CDK1 upon the nuclear translocation of cyclin B1 (CCNB1), and the removal of inhibitory phosphorylations at Thr-14 and Tyr-15 by the CDC25 family of phosphatases (reviewed in (Rhind & Russell, 2012) ). Consistent with the global activation of mitotic kinases observed by flow cytometry, immunofluorescence analyses revealed a generalized accumulation of nuclear CCNB1 in RPE cells treated with USP7i, which was phosphorylated at Ser-126, a CDK1-dependent site (Li, Meyer et al., 1997) (Figure   3A,B) . In addition, WB confirmed an increase of other CDK1-dependent phosphorylation events such as LAMIN A/C or MPM-2, together with a decrease in CDK1-Tyr15 phosphorylation, all of which are indicative of CDK1 activation ( Figure   3C ). Supporting this view, CDK1 inhibition rescued the generalized increase in H3S10 phosphorylation and MPM-2 reactivity that is observed upon USP7 inhibition (Figure 3D,E ). Moreover, we tested the effect of USP7 inhibitors in mouse embryonic fibroblasts (MEF) lacking CDK2, CDK4 and CDK6 (CDK2/4/6 KO), in which CDK1 drives all cell cycle transitions by interacting with the corresponding cyclins (Santamaria, Barriere et al., 2007) . MPM-2 and H3S10 phosphorylation presented a similar increase in Wild Type (WT) and CDK2/4/6 KO MEFs treated with USP7 throughout the cell cycle, further indicating that this activity is mediated by CDK1 (Figure 3F,G) .
CDK1 and CDC25A contribute to the toxicity of USP7 inhibitors
Finally, we evaluated if the premature activation of CDK1 plays a role on the toxicity of USP7 inhibitors, which are being developed as anticancer agents mostly based on their capacity to increase P53 levels (Li, Chen et al., 2002) . As mentioned above, a premature activation of CDK1 in S-phase cells leads to PCC, abnormal chromosome segregation and ultimately cell death (Aarts et al., 2012 , Duda et al., 2016 . Likewise, metaphase spreads prepared from RPE cells treated with USP7i revealed figures consistent with PCC and a significant increase in aberrant metaphases (Figure 4A,B) . Importantly, CDK1 inhibition significantly reduced the percentage of apoptotic cells induced by USP7i (Figure 4C,D) . We recently showed that the toxicity of inhibitors of the ATR kinase is also mediated by an increase in CDK1 activity, and which is alleviated by a deficiency in the CDK1-activating CDC25A phosphatase (Ruiz et al., 2016) . Similarly, CDC25A-deficient mouse embryonic stem cells were significantly resistant to USP7i-induced cell death (Figure 4E,F) . Hence, and regardless of the effect of USP7 inhibitors on P53, our data show that the toxicity of these compounds is due, at least in part, by a premature activation of CDK1. 
DISCUSSION
While the cell cycle has been intensively studied, our understanding of how or when mitosis is initiated remains incomplete. A passive model would be that a gradual build-up of CDK1 activity in G2 that, at some point, reaches a threshold sufficient to trigger mitotic entry. Alternatively, or in addition to this model, it has been long speculated that an S/M checkpoint constantly prevents mitotic entry before DNA replication is completed (Elledge, 1996 , Enoch & Nurse, 1991 , Hartwell & Weinert, 1989 ). In this model, G2 could de facto be considered as a "very-late S phase", where cells would have completed the replication most of their genome, with some difficult parts such as repetitive sequences or heterochromatin regions left to be copied. Interestingly, recent works have detected evidences of DNA replication persisting in mitosis, which could be exacerbated by conditions that perturb DNA replication (Eykelenboom, Harte et al., 2013 , Minocherhomji, Ying et al., 2015 .
The S/M checkpoint model also implies that replisomes will somehow elicit a "No-Mitosis" signal, that will disappear once replication is finished allowing for the progression into mitosis. Supporting this view, previous work revealed that the activation of mitotic kinases is coincident with the disappearance of PCNA foci (Akopyan, Silva Cascales et al., 2014) . This concept would be analogous to the Spindle Assembly Checkpoint (SAC), where every unaligned chromosome actively signals through the SAC to prevent the onset of anaphase (Musacchio, 2015) . In the S/M checkpoint, ongoing replisomes would be the signal that prevents CDK1 activation. One possibility could be that the single-stranded DNA generated at moving forks suffices to activate the ATR-dependent checkpoint, which limits CDK1 activity. Accordingly, ATR inhibition forces premature mitotic entry in cells that have unfinished DNA replication (Eykelenboom et al., 2013 , Ruiz et al., 2016 . In addition to kinases, our work here indicates that ubiquitin-based signaling networks also play a role in coordinating S and M phases, as the inhibition of a replisome- Intriguingly, CDK1 is among the factors that we previously found to be ubiquitinated in response to USP7 inhibition , and recent work has revealed that SUMOylation is inhibitory for CDK1 function (Xiao, Lucas et al., 2016) . One possibility could thus be that SUMO and ubiquitin play opposing roles in regulating CDK1 activity, although whether this occurs and how remains to be clarified.
Finally, our work also has important implications for the development of USP7 inhibitors as anticancer agents, an area in which efforts have recently intensified (reviewed in (Zhang & Sidhu, 2018) ). The currently accepted mechanism of action is the deubiquitination and stabilization of P53 due to the degradation of MDM2, the main E3 ligase targeting P53 for degradation by the proteasome (Li et al., 2002) . However, our previous work showing USP7 inhibition blocks DNA replication independently of p53 , together with the current data indicating that the toxicity of these compounds is alleviated by CDK1 inhibition or CDC25A deficiency, indicate that premature mitotic entry is likely to play an important role on the toxic effects of USP7 inhibitors. This information should be incorporated into the rationale for using these compounds, first because it indicates that p53-deficient cancer cells will also respond to the treatment, but also since it suggests that USP7 inhibitors are likely to synergize with other agents that promote mitotic entry. Besides its usefulness for cancer therapy, the work presented here provides direct evidence for the coupling of DNA replication termination with mitotic entry and identifies USP7 as a coordinator of this transition. 
MATERIALS AND METHODS
Cell lines
HCT116, U2OS and RPE cells (ATCC) were grown in DMEM with 10% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml) and glutamine (300 mg/ml). MEFs were grown in 15% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml) and glutamine (300 mg/ml). mESCs were grown on a feeder layer of inactivated MEF with DMEM (high glucose) supplemented with 15% knockout serum replacement (Invitrogen), LIF (1000 U/ml), 0.1 mM non-essential aminoacids, 1% glutamax and 55 µM b-mercaptoethanol.
Treatments
USP7 inhibitors P22077 (Merck Millipore), BAY 11-7082 (Santa Cruz) and the CDK1 inhibitor Ro3306 (Sigma) were dissolved in DMSO. Cells were incubated for the indicated times and doses with each inhibitor or an equivalent amount of DMSO.
Cell Synchronization
RPE cells were synchronized using a double thymidine block. Cells were incubated in the presence of 1 mM Thymidine for 16hrs at 37ºC. Then, cells were washed once in PBS and released in DMEM for 8hrs at 37ºC. The culture medium was replaced with DMEM containing 1mM Thymidine and cells were incubated for 16hrs at 37ºC. Again, cells were washed once and released in DMEM.
Immunofluorescence and High Throughput Microscopy
For immunofluorescence of MCM3, SUMO2/3, VCP, PCNA, POLD1, RFC2 and RPA2 soluble proteins were pre-extracted by mild detergent permeabilization with CSKI buffer (10 mM Pipes, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, and 0.5% Triton X-100) before fixation. For HTM, cells were grown on µCLEAR bottom 96-well plates (Greiner Bio-One) and immunofluorescence was performed using standard procedures. Analysis of DNA Replication by EdU incorporation was done using Click-It (Invitrogen) following manufacturers' instructions. In all cases, images were automatically acquired from each well using an Opera High-Content Screening System (Perkin Elmer). A 20x or 40x magnification lens was used and images were taken at non-saturating conditions. Images were segmented using DAPI signals to generate masks matching cell nuclei from which the mean signals for the rest of the stainings were calculated.
Protein extracts and Cell Fractionation
Whole cell extracts were prepared by lysing cells in 50 mM Tris, pH 7.5, 8 M Urea, and 1% Chaps. Cytosolic and nuclear extracts were prepared as described (Lecona, Barrasa et al., 2008) . Cells were scraped in cold PBS and washed twice with PBS. Cells pellets were resuspended in ice-cold hypotonic lysis buffer (10 mM HEPES, pH 7.9, 10mM KCl, 0.1 mM EDTA containing protease and phosphatase inhibitors), incubated on ice for 10 min, and then Nonidet P-P40 was added to a final concentration of 0.1%. After 3 min at room temperature, cells were vortexed and the cytosolic fraction was obtained by centrifugation at 2500 g for 5 min. Nuclei were washed once in hypotonic lysis buffer and then resuspended in hypertonic extraction buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA containing protease and phosphatase inhibitors). After 1 hr shaking at 4ºC, the extract was centrifuged for 5 min at 16000 g. The nuclear extract is collected and the chromatin fraction was then extracted in 50 mM Tris, pH 7.5, 8 M Urea, and 1% Chaps, shaking at 4ºC for 30 min. Chromatin fraction was obtained after centrifugation for 5 min at 16000 g. Protein concentration was determined using the BioRad Protein Assay.
Immunoprecipitation of His-ubiquitin
Transfection of RPE cells with the plasmid pCl-His-hUb (Addgene, #31815) was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After cell fractionation as mentioned before, the chromatin fraction was diluted in 8 M urea/100 mM phosphate/ 500 mM NaCl/30 mM imidazole/0.5% NP40, and then incubated in Ni-NTA Agarose (Qiagen), for 1.5 h, rotating at RT. 
Flow Cytometry
For the analysis of H3S10P and MPM-2, cells were trypsinized, washed with cold PBS once and fixed in suspension by the addition of cold 70% ethanol. Cells were incubated for 30 min on ice and maintained at -20ºC or processed immediately after fixation. Cells were centrifuged at 4000 rpm for 5 min and then incubated with the specific antibodies in PBS/0.05% Tween20/ 3% BSA for 2 hrs at RT. Cells were washed in PBS/0.05% Tween20 and incubated with secondary antibodies in PBS/0.05% Tween20/ 3% BSA for 1 hr at RT. Finally, cells were washed with PBS/0.05% Tween20 and resuspended in PBS containing 100 µg/ml RNase. DNA content was visualized incubating the cells with 100 µg/ml PI. For the analysis of apoptosis, cells were trypsinized, centrifuged and resuspended at 10 6 cells/ml in cell culture medium containing 10 µg/ml Hoechst and 40nM TMRE. Then, cells were incubated for 30 min at 37ºC. All samples were analysed in a BD LSRFortessa cell analyser. The results were analysed using the FlowJo software (FlowJo, LLC).
RNA interference
Transfection of RPE cells with control (Qiagen; Cat#1027281) or USP7 targeting siRNAs (USP7 siRNA #1 (Cat#SI00052283) and #2 (Cat#SI00052290)) was carried out using Lipofectamine RNAimax (Invitrogen) according to the manufacturer's instructions.
Metaphases
Cultured cells were arrested at mitosis with 100 ng/ml Colcemid (GIBCO/BRL) and after 2 hours were collected and resuspended in a hypotonic solution (0.075 mM of KCl). Cells were incubated 20 minutes at 37°C and fixed with Carnoy´s buffer (methanol-glacial acetic acid (3:1)). To obtain metaphase spreads cells were dropped on slides and stained with Giemsa.
Data analysis
Data were represented with the use of the Prism software (GraphPad Software).
The statistical analysis was also carried out with Prism, using the specified statistical comparison where indicated in the Figure Legends. 
Antibodies
The following antibodies were used in this study: H3S10P (Merck Millipore, 06-570), (E) Immunofluorescence analysis of chromatin-bound SUMO2/3 (green) and MCM3 (red) levels in U2OS cells that were either untreated (CONTROL) or after treatment with 50 µM USP7i for 4 h. DNA was stained with DAPI (blue). The overlay for SUMO2/3 and MCM3 is shown on the right. Scale bar, 10 µm.
(F) Immunofluorescence analysis of chromatin-bound PCNA (green) and POLD1 (red) levels in U2OS cells that were either untreated (CONTROL) or after treatment with 50 μM USP7i for 4 h. DNA was stained with DAPI (blue). The overlay for PCNA and POLD1 is shown on the right. Scale bar, 10 μm. DNA content was evaluated with Hoechst, and the mitochondrial membrane potential was measured by TMRE. The percentage of apoptotic cells (TMRE negative, red) is indicated for each condition from a representative experiment.
The experiment was repeated 3 times using 3 independent CDC25A-deficient mESC lines. The quantification is shown in (F). (*p<0.05, t-test). Figure S2 . (Related to Fig. 2) . (A-B) Flow cytometry data illustrating the levels of histone H3S10P (left) and MPM-2 (right) in RPE (A) and U2OS (B) cells that were either untreated (CONTROL, black) or after a treatment with 25 or 50 μM USP7i for 4 hrs (red), respectively. DNA content was measured with PI. The experiments were repeated 2-3 times and one representative result is shown. (C) Flow cytometry data illustrating the levels of MPM-2 in RPE cells that were either untreated (CONTROL, black) or after treatment with 25 μM of an independent USP7 inhibitor (BAY 11-7082) for 2 hrs (red).
